drugset / Trial / NCT06360601
Intravenous Labetalol Versus Hydralazine in Preeclampsia
RandomizedParallel-groupTriple-blindPrevention
Summary
We study the effect of intravenous labetalol versus hydralazine in sever preeclampsia patients on cerebral blood flow and neurological outcome
Timeline
- Start
- 2024-04-01
- Primary completion
- 2024-11-20
- Completion
- 2024-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Hydralazine | Small molecule | 5 mg | Intravenous |
| Comparator | Labetalol | Small molecule | 20 ml | Intravenous |